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Heart failure (HF) is a complex clinical syndrome associated with a high mortality
rate, frequent hospitalizations, and significant symptom burden that often contributes to a
poor quality of life. Palliative care (PC), historically associated with managing the endof-life needs of cancer patients, offers opportunities to improve health-related quality of
life for those with HF in conjunction with, or instead of, life-prolonging medical
therapies. The aim of this project was to evaluate and address patient-specific needs for
those with advanced HF. The Kansas City Cardiomyopathy Questionnaire (KCCQ) was
administered to patients recently hospitalized for acutely decompensated heart failure
who were referred to a hospital-affiliated heart failure clinic for ongoing disease
management. Of 26 questionnaires administered, 10 patients met inclusion criteria and
agreed to participate. These patients were randomly allocated in a 1:1 fashion to one of
two groups, with either usual care or usual care plus PC intervention. All received
guideline-directed HF treatment; the intervention group also participated in one-on-one
semi-structured interviews with a nurse practitioner experienced in both HF management
and PC. After three months, patients were re-evaluated with the KCCQ, and baseline and
3-month results were compared and analyzed using the Wilcoxon signed-ranked test.
Although no statistically significant change was noted, clinically significant change was
found through validated KCCQ score changes in both groups. This project emphasized
the need for concurrent guideline-directed HF therapy and palliative interventions. Longterm, consistent care is essential for this patient population to achieve patient-centered
care that is congruent with their needs and wishes.
Keywords: Heart failure, palliative care, shared decision-making, health-related quality of
life, patient-centered care, advance care planning
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Integrating the Palliative Care Principles of Shared Decision Making and Advance
Care Planning into Heart Failure Management: A Pilot Project
Identification of Problem
Heart failure (HF) is a chronic, progressive disease that presents a significant
burden to patients, families, and health systems in the U.S. HF is a leading cause of
hospitalization, with frequent readmissions (Feltner et al., 2014). Morbidity and mortality
rates are high, contributing to nearly 10% of all deaths, and has a five-year mortality
rate of about 50% (CDC Fact sheet, 2016). Incorporating palliative care services into
standard treatment for advanced HF is largely presumed to improve health-related quality
of life (QoL) and to provide patients and families the opportunity to discuss treatment
options and wishes (Teuteberg & Teuteberg, 2016). Another proposed benefit of
palliative care is the opportunity to manage common symptoms of dyspnea, fatigue, pain,
depression, edema, and anxiety (Adler, Goldfinger, Kalman, Park, & Meier, 2009).
Although most HF management guidelines and consensus statements recommend the
integration of specialist-directed palliative care into the management of HF, less than
10% of qualified patients receive these services (Xie, Gelfman, Horton, & Goldstein,
2017).
Palliative Care (PC) is defined by the World Health Organization (WHO) as an
approach to care that focuses on improving the quality of life of patients facing serious,
complex, or life-threatening illness (World Health Organization, 2018). In 2015, the
WHO expanded the definition and goals of PC to include application early in the disease
process, in conjunction with treatments aimed at prolonging life (World Health
Organization, 2018). Redefining the terminology has expanded inclusion criteria to
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patients with chronic illnesses, including those where prognosis and life expectancy were
difficult to predict, and is not limited to a particular care setting (Kydd, 2015). PC is
frequently thought to be interchangeable with hospice, or end of life care; however, PC is
focused on patient and familial support throughout the course of serious illnesses,
regardless of life-prolonging or curative treatment (Adler et al., 2009).
By providing palliative measures throughout the continuum of illness, care
became patient- and family-centered, thus addressed their physical, intellectual,
emotional, social, and spiritual needs (Mulvihill, 2015). Facilitating patient autonomy,
access to information, and informed choices encouraged collaboration and coordination
of high-quality care (Mulvihill, 2015). Palliative medicine strives to improve patients’
quality of life using a holistic, multidisciplinary approach to address physical,
psychological, and spiritual needs (Adler et al., 2009).
HF is a complex clinical syndrome resulting from other diseases or injuries such
as myocardial infarction, valvular disease, hypertension, or atrial fibrillation,
which damages the myocardium and affects the heart’s ability to pump
effectively (Treece et al., 2017). Heart failure is classified as either systolic, characterized
by low ejection fraction (EF) and reduced left ventricular contractility; or
diastolic, characterized by impaired relaxation of the heart muscle resulting in abnormal
left ventricular filling capacity, thus maintaining a preserved EF despite decreased
cardiac output (Treece et al., 2017). This failure of the myocardium to pump or to relax
adequately is representative of the end-stage sequelae of other diseases, typically
those involving the cardiac or pulmonary systems, though other causes cannot be
excluded (Treece et al., 2017). Advances in medical management have improved
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mortality for patients with systolic heart failure, however these treatments have not
proven beneficial for those with diastolic failure (Treece et al., 2017).
HF is progressive in nature and has a high mortality rate and is associated with a
poor quality of life in spite of recent advances in treatment options (Mentz et al., 2014).
For many patients the disease progression is disabling. Common symptoms of HF include
dyspnea and angina, progressing from occurring primarily with exertion to occurring
even at rest. Fatigue is a common complaint and negatively affects quality of life.
Orthopnea and paroxysmal nocturnal dyspnea interfere with sleep and rest, and persistent
edema may limit activity (Treece et al., 2017). The disease trajectory is typically marked
with periods of relatively stable symptoms interrupted by acute decompensations.
Functional decline may be abrupt or incremental, with about 50% of HF patients dying
abruptly from sudden cardiac death, while the other half die after gradual debilitation and
decline (Treece et al., 2017). Prognostication is difficult because the disease trajectory
varies widely from patient to patient (Treece et al., 2017).
Advanced stages of HF carry significant symptom burden and patients commonly
have multiple comorbidities. Although most HF guidelines and consensus statements
recommend PC as a component of routine HF management, PC typically is not
introduced until the patient enters the final stages of life and becomes eligible for
hospice (Treece et al., 2017). Unlike hospice, PC services are available to patients at any
stage of disease, even those pursuing curative or life-prolonging treatment. Care is
focused on maintaining quality of life through shared decision-making, symptom
management, establishing personal goals, advanced planning, and spiritual and
psychosocial support.
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Significance to Health Care
The prevalence and impact of HF places a significant burden on the health care
system and is expected to increase further as the population of the U.S. ages. Within the
U.S., 6.6 million adults are diagnosed with HF, and the American Heart
Association expects this number to rise to almost 10 million by 2030, with 670,000 new
cases diagnosed each year (American Heart Association [AHA], 2013). HF accounts for
more than 1 million hospitalizations and 3.6 million medical clinic and emergency room
visits each year (AHA, 2013). Direct medical costs for treatment are expected to increase
from $21 billion in 2012 to $53 billion by 2030 (AHA, 2013).
Goals and Objectives
This project’s goal was to improve consistency of patient-centered care for those
with advanced HF by incorporating PC principles of shared decision-making, medical
management, and psychosocial support into routine outpatient care. These efforts support
the goals of the heart failure clinic (HFC) to improve patient satisfaction and quality of
life (QoL), to support caregivers, and to decrease costs as integral components in the
management of patients with advanced HF. Clinical and medical management of patients
treated in the HFC excels through consistent use of guideline-directed medication
therapy, aggressive management of comorbidities, diagnostic evaluation for new or
worsening disease, and referral to specialists; however, a gap still exists between
guideline-recommended PC measures and clinical practice. Proposed means to bridge
this gap included identifying and addressing QoL limitations using the Kansas City
Cardiomyopathy Questionnaire (KCCQ), incorporating shared decision-making
principles to involve patients’ goals into treatment plans, and investigating billing
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methods to capture reimbursement for services as provided by Centers for Medicare and
Medicaid Services (CMS).
PICOT Question
For patients with advanced heart failure, how does integrating the palliative care
principles of shared decision making and advance directives into the standard treatment
plan, compared to those who receive usual care, influence health outcomes in a threemonth period.
Review of Evidence
Search strategy
The University of Alabama at Birmingham library database was searched to
find evidence of the impact of PC on HF patients in an outpatient setting. The databases
examined for adult human studies published between 2009 and 2018 include CINAHL,
OVID, Cochrane Review, PubMed, Joanna Briggs Institute for EBP Database, and
Google Scholar. Articles not available in full-text were requested through interlibrary
loans. The search was limited to scientific, academic, peer-reviewed journals, and clinical
trials.
Key search terms included: heart failure or congestive heart failure; palliative
care; shared decision-making; communication; patient-centered care; advance
directives; and health-related quality of life. Articles for review fell into three primary
categories: health-related quality of life, communication and shared decision-making, and
clinical guidelines and expert consensus statements.
Within the cardiology literature, there is a paucity of primary research and clinical
trials pertaining to palliative care measures in HF treatment programs. However,
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secondary data sources provided validation that this topic is being reviewed as pertinent
to practice. In the past year several changes have been made to AHA and American
College of Cardiology (ACC) Guidelines to implement palliative care into routine HF
management. Palliative medicine journals provide more qualitative studies and offered
methods to bridge the gap between traditional oncology-focused palliative interventions
and those that are appropriate for heart failure patients.
Health-Related Quality of Life
Implementing PC principles into the routine treatment of HF remains in the early
stages of discovery. There is a scarcity of quantitative clinical trials to guide evidencebased practices for integrating PC into HF management. Even within the existing
research there is variance in implementation strategies, such as appropriate timing, site of
care, who provides the PC intervention, and scales of measurement.
In their groundbreaking randomized, controlled trial, Rogers and his team
evaluated the impact of an interdisciplinary PC intervention on HF-related symptoms in
patients with advanced HF (2017). In this large, single-site study, the authors used the
Kansas City Cardiomyopathy Questionnaire (KCCQ) and the Functional Assessment of
Chronic Illness Therapy-Palliative Care (FACIT-PAL) surveys to measure health-related
quality of life (HRQoL) of patients who had been recently discharged from the hospital.
The intervention was performed by PC specialists and consisted of assessment and
management of physical symptoms, psychosocial and spiritual concerns, and advance
care planning (Rogers et al., 2017). In this prospective, 2-arm, single center clinical trial,
150 patients with advanced HF were randomized to two groups and received usual care
alone (UC) or UC plus palliative care intervention. Surveys were administered at baseline
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and at designated intervals throughout the study. Results of both KCCQ and FACIT-PAL
assessments showed clinically significant benefits of embedding a specialized palliative
intervention in the routine treatment of patients with advanced HF, compared to those
with UC alone, though no statistical significance was reported (Rogers et al, 2017). These
findings were mirrored in a randomized controlled trial conducted by Brännström and
Boman (2014), the aim of which was to evaluate the effects of an intervention using
Palliative advanced home caRE and heart FailurE caRe (PREFER) on patient symptom
burden and quality of life. In this open, non-blinded study design, 36 patients were
randomized into two groups, an intervention group and a UC group. Usual care was
provided by general practitioners and the nurse-led heart failure clinic. Patients in the
intervention group received UC and palliative interventions, led by a specialized PC
team. Quality of life was assessed at baseline and routinely throughout the study using
three validated questionnaires: The Euro Qol-5D: health-related quality of life (EQ-5D),
the Edmonton Symptom Assessment Scale (ESAS), and the Kansas City
Cardiomyopathy Questionnaire (KCCQ). Results indicated that health related quality of
life improved significantly in the intervention group at six months by all three
questionnaires (Brännström & Boman, 2014).
In a 2011 qualitative study by Bekelman and colleagues, 33 adult outpatients with
symptomatic HF and their families were separately interviewed to assess needs, concerns,
and preferences pertaining to their HF treatment. The researchers’ primary goal was to
identify unmet patient needs, salient concerns, and preferences to develop and guide a
non-oncology, non-hospice palliative intervention in an outpatient HF setting. Using
the KCCQ to gain patients’ perceived HF-specific QoL, these researchers found that
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patients desired assistance in adjusting to the functional limitations of HF, help
understanding the future course of the disease, relief of symptoms, and the involvement
of family members in planning care. Many patients desired these elements early in the
disease process rather than waiting until the disease progressed to advanced stages
(Bekelman et al., 2011). Because PC is more widely used in the oncology setting, it is
important to recognize the importance of customizing care to the needs of the patients
with chronic diseases, particularly those difficult to prognosticate. Kavalieratos and
others (2014) conducted a review of data of 1031 patients from the Palliative Care
Research Review to evaluate the differences of care given to patients with cancer
compared to those with HF. Their findings revealed that although physical and
psychosocial needs of patients in these two groups are similar, patients with HF reported
dyspnea more frequently than those with cancer. In spite of a similar symptom
burden, there was a treatment gap in how symptoms were managed, with a lack of
documented intervention for distress reported as moderate or severe (Kavalieratos et al.,
2014).
Patients’ quality of life is impacted by the high symptom burden associated with
HF. Two separate studies explored the effects of PC services on patients with HF.
Evangelista and colleagues (2012) conducted a prospective comparative study to examine
the impact and feasibility of outpatient palliative care consultation on the symptom
burden, depression, and quality of life of patients with symptomatic heart failure. In this
single site study, the researchers recruited 36 patients who were hospitalized for acute HF
to participate in an outpatient PC consultation after discharge. During this consultation,
multiple elements of the disease were addressed, including physical, psychosocial, and
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spiritual aspects. The researchers then conducted phone interviews three months later to
gather information about socioeconomic and clinical data. Several domains of HF were
assessed, including: depression, using the Patient Health Questionnaire (PHQ); physical
symptoms, using the Edmonton Symptom Assessment Scale (ESAS); and quality of life,
using the Minnesota Living with Heart Failure Questionnaire (MLHFQ). The authors
compared baseline data to results obtained after three months to a similar control group
receiving UC only. Results indicated that both groups reported improvement in symptom
burden, depression, and quality of life, though the intervention group had greater
improvement than those receiving UC alone (Evangelista et al., 2012).
In a separate study, Evangelista and her colleagues (2014) conducted a
descriptive-exploratory study to examine whether the type and frequency of palliative
care services impacts patients’ symptom burden in advanced heart failure. In this study,
referred patients were allowed to choose either a single palliative care consultation, or a
consultation plus ongoing support. For those with ongoing support, referrals to a
palliative care specialist, pharmacist, and social worker were arranged. Pharmacologic
interventions were provided for symptom relief, and included opiates, anti-depressants, or
both. After three months, the authors re-evaluated both groups. Their findings suggested
that those who received additional palliative care services showed a clinically relevant
improvement in symptom burden (Evangelista et al., 2014). Similar findings were
reported by Schwarz and colleagues (2012) in a pilot study conducted to determine the
effects of a PC intervention on symptom management, clarification of the goals of
therapy, advance care planning, hospice referral, and end-of-life care for patients who
were referred for heart transplant or ventricular assistive device (VAD). These findings
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were supported in an article by Ghashghaei, Yousefzai, & Adler (2016) who
recommended that PC consultation be provided for all HF patients, including those who
are pursuing VAD, heart transplant, and other advanced therapies focused on prolonging
life to ameliorate symptoms, facilitate care planning, provide emotional support to relieve
suffering, and decrease unnecessary costs to patients. The authors also emphasized the
need for physician education in PC, and to improve the underuse of PC services. This
study found that patients reported moderate to significant improvement on HRQoL with
the intervention. Interestingly, researchers in the above studies report finding no increase
in the life expectancy of patients.
Systematic reviews by Siouta and others (2016) and Kavalieratos and colleagues
(2017) found that while most clinicians supported early PC integration into the routine
management of advanced HF, communication of complex decision-making and end-oflife topics are rarely initiated, resulting in patients who are less informed about their
disease process and treatment options. They found that there are limited opportunities to
discuss Advance Directives, emotional, or spiritual concerns. Siouta and associates
(2016) noted a lack of a standardized and universal definition of PC, while Kavalieratos
and colleagues (2017) pointed out that little emphasis is placed on QoL, complex
decision-making, or providing PC concurrently with life-prolonging or advanced
therapies.
These studies support the case for palliative care to be integrated into the standard
management of HF. Treatment of HF should extend beyond medications that affect
morbidity and mortality and include measures to ameliorate the distressing symptoms of
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HF to improve patients’ QoL. More longitudinal and multi-center studies are needed to
establish evidence and standards for PC intervention that best improve patients’ HRQoL.
Communication and Shared Decision Making
In March 2001, the Institute of Medicine (IOM) released the landmark
publication Crossing the Quality Chasm: A New Health System for the 21st Century. In
this report, the IOM proposed a new approach to the American health care system and
how health care is delivered, in an effort to bridge the gap of what U.S. health care is, and
what it could be. This report proposed six specific aims to improve health care, one of
which is patient-centered care, when care is provided that is “respectful of and responsive
to individual patient preferences, needs, and values, and ensuring that patient values
guide all clinical decisions” (National Academies Institute of Medicine [IOM], 2001,
p.3). Supporting this aim, the Patient Protection and Affordable Care Act (ACA) (2010)
created a program to facilitate shared decision-making with the purpose of facilitating
collaboration between patients, caregivers, and clinicians to create health care plans that
incorporate patient wishes with sound and reasonable care options to formulate
individualized medical plans (Office of the Legislative Counsel, 2010). The ACA also
called for the development of decision aids, shared decision-making programs, and
metrics to gauge the quality of decision-making (Office of the Legislative Counsel,
2010). Progression toward this transformation in the delivery of care requires a paradigm
shift on the part of clinicians, patients, and caregivers alike.
Although communication is an essential component of both PC and HF
management, clinicians tend to discuss only the medical management of the disease.
Frequently the focus of patient-provider conversations is on ways to improve function
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and prolong life. However, because HF is a life-limiting disease and there is no known
cure, patients and their families should be informed of the elevated risk of sudden cardiac
death or gradual demise (Goodlin, 2009). In fact, it is the legal and ethical responsibility
of the health care provider to narrow the diagnostic and treatment options to those that
are medically reasonable to consider (Allen et al., 2012). In fact, increasing patients’
awareness of the nature of HF is not only legally and ethically prudent, but may also
serve to increase compliance with medications and dietary restrictions, and to provide the
patient with an opportunity to plan for a worst-case scenario (Goodlin, 2009).
Two of the reviewed studies noted that a crucial component of
communicating with HF patients and their families was advance care planning and
designating a health care proxy (Adler et al., 2009; Gerlich et al., 2012). Addressing these
issues early in the disease provided an opportunity for discussions about personal health
care wishes and goals. A qualitative, longitudinal study conducted by Gerlich and
associates (2012) found that by establishing patients’ goals of care early in the disease
process, patients noted an increase in fulfillment of health-related and personal goals, and
caregivers reported a reduction in stress and anxiety. These goals should be specific and
identify their wishes in circumstances such as cardiopulmonary arrest or intubation, and
patients should be assured that preferences can be changed at any time (Adler et al.,
2009). The difficulties associated with this process include the time involved in
conducting such discussions, a lack of clinician training in addressing these topics, and
the inability of some patients to articulate decisions that are congruent with their stated
goals (Allen et al., 2012).
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As U.S. health care moves toward a more patient-centered approach, the
concept of shared decision-making is gaining momentum. Collins & Storrow (2013)
described shared decision-making as a collaborative interaction between patients,
caregivers, and providers that lead toward care that is predicated on mutual agreement.
The crux of patient-centered care is that the focus is moved away from the disease and
focused on the patient and family systems (Collins & Storrow, 2013). The authors noted
that this active engagement is an especially important component when health care
decisions have significant consequences and persisting implications (Collins & Storrow,
2013).
Clinical Guidelines and Expert Consensus Statements
Current HF literature recommends integrating PC into the routine treatment of
patients with advanced HF, and multiple agencies have outlined methods to do so. The
Joint Commission requires that the HF team be prepared to address PC with patients, and
to incorporate individualized advanced care planning into patient care in order to receive
specialized credentialing (The Joint Commission, n.d.). In the ACC/AHA Clinical
Guideline for the Management of Heart Failure, task force members developed
comprehensive guidelines to manage HF, in which supportive and PC strategies are
considered an appropriate component of treatment, whether as sole focus of care or in
conjunction with life-prolonging measures (Yancy et al., 2013). An AHA policy
statement asserts that attempts to prolong final stages of HF increase the burden of
physical limitations and suffering onto patients, their families, and the medical system,
and recommend that offering PC to these patients may lead to more conservative and less
costly treatment, and reflect the patients’ personal goals (Heidenreich et al., 2013). In an
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AHA Scientific Statement, the authors promoted the importance of shared decisionmaking to increase the probability of high-quality decisions which emerged from options
that are medically reasonable and are in accordance with the values and goals of fullyinformed patients (Allen et al., 2012). Teuteberg and Teuteberg (2016) noted that
advanced care planning and making complex decisions increase in importance as HF
progresses into advanced stages of the disease. This is especially true in conversations
that include decisions about advanced therapies, such as inotrope therapy, circulatory
support interventions, heart transplant, and left ventricular assistive device implantation
(Teuteberg & Teuteberg, 2016).
The call for normalizing PC as a part of HF management led the ACC to create a
decision pathway for optimizing HF treatment in which seven key principles of PC are
outlined, and specific actions are offered to help health care providers integrate these
principles fully into practice. The principles outlined in the decision pathway are: 1) to
reduce suffering through pain and symptom management; 2) meticulous management of
HF therapies; 3) specialized palliative consult as needed for further amelioration of HF
symptoms refractory to guideline-directed therapy; 4) assist with major treatment
decisions over time and utilize patient decision aids to help frame options; 5) ongoing
preparedness discussions and shared decision-making; 6) use of clinical milestones that
affect disease trajectory to calibrate patient expectations, and 7) to assist quality survival
periods between aggressive care and comfort only by revising medical regimen and
frequently weighing benefits and burdens of specific treatments and medications (Yancy
et al., 2013).
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In spite of increasing calls to implement standards that include palliative
measures in the treatment of heart failure, few patients receive these interventions until
they are at the end of life. There is a discrepancy between expert recommendations and
guidelines and the resources available to study and implement these measures. Without a
solid base of evidence, utilization of these recommendations will be limited.
Conceptual Framework
The Quality Caring Model (QCM) (see Figure 1), designed by JoAnne Duffy to
guide research and practice, asserts that the nature of nursing is centered on relationships,
and the association of those relationships with quality health outcomes (Duffy &
Hoskins, 2003). The QCM emphasizes the importance of relationships in the context
of health care and focuses on the independent relationships of nurses with patients, as
well as the collaborative relationships between nurses and other health care professionals
to promote improved patient outcomes (Duffy & Hoskins, 2003). This model provides a
structure for integrating these principles into patient relationships. The four primary
concepts of this relationship-centered theory are: 1) humans in relationships;
2) relationship-centered professional encounters; 3) feeling “cared for”; and 4) selfadvancing systems (Smith & Parker, 2015). In 2005, Dr. Duffy and her colleagues
developed an in-home caring-based intervention for recently hospitalized older adults
with HF (Duffy, Hoskins, & Dudney-Brown, 2005). Based on the QCM, a team of nurse
researchers developed a nursing intervention to attain the goals of improving patient and
system outcomes in a practical, low-cost design that could be completed by staff nurses
as part of their daily work (Duffy et al., 2005). The premise was to develop caring, longterm relationships between nurses and these patients to facilitate individualized
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understanding and help specific to each patient’s needs (Duffy et al., 2005). It is in
establishing this rapport and trusting relationships that promote shared decisionmaking to assist patients to clarify personal goals and wishes.
Humans in Relationships
The QCM seeks to demonstrate the multiple dimensions of humans with
unique characteristics that set them apart from others, and as a result, how these attributes
affect patients and their family’s interactions with others in their given environment
(Smith & Parker, 2015). Caring relationships promote positive outcomes such as
preserving dignity, protection from harm, increased knowledge of self, improved health,
and inner balance (Duffy & Hoskins, 2003). Caring relationships are believed to
positively impact not only patients and their families, but health care providers as
well (Duffy & Hoskins, 2003).
For patients with HF, a disease characterized by exacerbations that impact routine
activity followed by periods of recovery, relationships with others often become stressed
as the disease progresses. Therefore, in times of crisis, reliance on others increases and
reflects the importance of interdependent relationships on many levels, personal and
professional, making this theory an appropriate model for palliative care (Davidson,
Cockburn, Daly, & Fisher, 2004).
Relationship-Centered Professional Encounters
Caring is typically considered the focus of a nurse’s work, and relationships with
patients and their families is central to the concept of PC. Nurses are often the cohesive
element in multidisciplinary heath care teams, such as those demonstrated in palliative
medicine. Collaborative relationships promote respect for the roles of other team
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members and disciplines, shared responsibilities, and validation of others’ work (Duffy &
Hoskins, 2003)
Relationships with patients and their families are a critical component of PC.
Illness is a time of vulnerability. Nurses, therefore, have a responsibility to initiate,
cultivate, and maintain intimate, interpersonal relationships. Relationships that are
intentional and aimed at health and healing have the potential to impact patients’ overall
health (Duffy & Hoskins, 2003). As a result, non-hospice PC services are currently
emerging as a means to improve mortality, to decrease hospitalizations, and to improve
patient outcomes (Duffy & Hoskins, 2004).
Feeling Cared-For
Palliative care exhibits a unique type of caring that comes from “specialized
knowledge, attitudes, and behaviors that are specifically directed toward health and
healing” (Smith & Parker, 2015, p. 394). Patients and families are encouraged to
create change and advancement, which leads to positive emotions and behaviors such as
beneficial risk taking, and to take part in the decision-making process which results in
healthy new decisions or actions (Smith & Parker, 2015). Likewise, PC maintains
patient dignity by honoring wishes, promoting acceptance of the disease process,
providing means for management of distressing symptoms which ultimately improves
patient-defined positive outcomes (Smith & Parker, 2015). This patient-familypractitioner interrelationship establishes trust and leads to discussions of difficult topics
related to HF, such as prognosis, disease progression, and desired levels of care in
advanced stages.
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Self-Advancing Systems
Self-advancing systems are described as progressive phenomena that develop
over time and reflect a positive dynamic process that impacts the well-being of a system
or individual (Smith & Parker, 2015). Advancements are driven by caring relationships
and emerge over time via these interpersonal connections, through a dynamic process that
represents quality in the QCM (Smith & Parker, 2015). For older adults with advanced
HF, performing self-care and activities of daily living is often compromised as a result of
the disease process as well as other physical and socioeconomic confounding
factors (Duffy et al., 2005). They often have unique needs that are not met with available
resources, and the fragmentation of current health care leads to access barriers and
follow-up care (Duffy et al., 2005). Self-advancing systems serve to provide a foundation
for patient-centered care and mutual problem-solving.
Project Implementation
Ethical Considerations
Approval from the IRB committees of both the hospital (see Appendix A) and the
University of Alabama (see Appendix B) were obtained prior to initiating this scholarly
project. Informed consent was obtained from all participants in Group A. Interviews were
conducted in an office separate from the open clinic, but in the same suite. No
preferential treatment or compensation was given to those participating in the project.
Written and electronic records containing any Protected Health Information (PHI) were
maintained in a locked file.
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Setting
The Heart Failure Clinic (HFC) is a hospital-affiliated, nurse practitioner (NP)led outpatient clinic. The role of the clinic is to provide ongoing guidelinedirected management and support for patients with acute and chronic HF, with the goals
of improving patient outcomes, decreasing frequency of HF-related hospitalizations, and
optimizing resource utilization. Patients’ scheduled appointments are made as indicated
by health status, medication stability, and ongoing evaluation. Initial clinical
information is collected by registered nurses (RNs), and evaluation and treatment are
performed by NPs. Physician support is available. The HFC is managed by an NP who is
actively involved in program development, functions as a liaison between the clinic and
hospital administration, and represents the clinic within the community and hospital
setting.
Treatment is focused on managing the disease process with the intent to slow
progression and decrease frequency of acute decompensations. An average of 45-60
patients are seen daily by a staff of NPs, RNs, patient care technicians, and physicians.
Medical treatment is guided by the AHA Get with the Guidelines (GWTG) for treatment
of HF using current best-practice strategies (American Heart Association, 2017). Patient
population includes adult patients, aged 19 years and older, although approximately 75%
of patients are 65 years and older. The gender distribution is approximately 60% males,
40% females, and race distribution is 60% African American, 35% Caucasian, and 5%
are of Hispanic, Asian, and Middle Eastern descent.
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Sample and Participant Selection
Eligibility criteria for inclusion in the project was defined as follows: adults 19years and older, with New York Heart Association (NYHA) Class III-IV symptoms (see
Table 1) and/or with AHA Stage C-D disease (see Table 2) who score 60 or below on the
Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary score (OS).
Gender, age, and race information were collected for reference only after completion of
the project. Clinical judgment, prognostic indicators, and clinical milestones (disease
progression refractory to optimized therapy, increased symptom burden, and recurrent
hospitalizations) were used to guide appropriateness for participation.
Newly enrolled patients during the 30-day recruitment period were administered
the KCCQ (see Appendix C) at their first appointment by the primary RN. Those whose
baseline KCCQ OS score was 60 or below were considered eligible for inclusion and
were asked to participate in this project using a prepared script (see Appendix D).
The patients who met inclusion criteria and agreed to participate (n=10) were randomly
allocated in a 1:1 fashion into two groups, Group A (n=5) or Group B (n=5). Group
A received usual care plus the palliative intervention (UC+PC) in the HFC, while Group
B received UC alone. The UC component was managed by the HFC staff utilizing
guideline directed therapies, medication titrations, and ongoing monitoring of end-organ
function. The PC intervention was conducted by an NP dually trained in HF and PC.
There were 26 KCCQs administered in the one month of recruitment. Of those, 19
patients met the inclusion criteria using a convenience selection strategy and were
approached to participate in the project. Of these 19, three patients declined to participate,
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and six were lost to follow-up. Seven patients did not meet inclusion criteria, thus were
excluded.
Project Design
After obtaining informed consent (see Appendix E), face-to-face meetings were
scheduled with each patient in Group A. The intervention plan included individual semistructured, goal-directed conversations about the patient’s wishes, options for care, and
advance care planning. Interviews consisted of open-ended questions to determine patient
readiness to participate in shared decision-making, address advance directives, and to
help patients understand disease trajectory and prognosis (see Appendix F). Patientreported quality of life measures were discussed using baseline KCCQ scores to address
those symptoms with greatest impact on that patient's life, leading to individualized goalsetting and attainment strategies.
The KCCQ is a validated, reliable, widely used self-administered 23-item tool
that quantifies six HF-specific domains and two summary scores, the Clinical Summary
(CS) score and the Overall Summary (OS) score (Spertus, 2016). The selected cut-off
score for inclusion was an OS score of 60. Scores are calculated and transformed into
values that range from 0-100, with higher scores representing better health status and
patient-perceived HRQoL (Rogers et al., 2017). Licensure to use the KCCQ was
purchased through Outcomes Instruments, LLC (see Appendix G).
Detailed discussions to fully inform patients of treatment options included disease
trajectory, prognostic indicators, and the benefits and burdens of available advanced
therapy options. Medications, titrations, and rationale for each were discussed. If device
implantation was being considered, such as automated implantable cardioverter
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defibrillator (AICD), or implanted volume monitoring devices, the risks and
benefits were explained. Advanced therapy options for treatment of end-stage heart
failure include inotrope infusions, ultrafiltration, implantation of left ventricular assist
device (LVAD), and heart transplant implications were discussed if appropriate. Careful
word choice was imperative to appropriately inform patients without causing undue fear.
Patients were offered the Alabama Advance Directives documentation to review
(see Appendix H). They were also be given the opportunity to discuss this form in detail
if desired, however none accepted during the project.
Participants were queried about symptoms, which were then discussed
with pharmacological and nonpharmacological treatment options. Spiritual and
psychosocial concerns were addressed based on patient preference.
Analysis
A total of 26 KCCQs were completed during a one-month period. Of these, 19
met criteria to participate. The KCCQ OS score at baseline and 3-months were selected
as the primary indicator of change in HRQoL between the two groups, UC or
UC+PC intervention. Primary endpoints were measured by changes in baseline and 3month OS scores on KCCQ. A 5-point change in the KCCQ OS score is the smallest
increment that is considered clinically significant for individual patients (Pokharel et al.,
2017).
Statistical analysis was performed using SPSS 25.0 software on the primary
endpoint of measurement of QoL using the KCCQ OS score. The sample size was 10,
(five per group), though only two post-intervention scores were obtained from Group A,
thus not meeting criteria for an adequate sample size of at least three to measure
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correlation coefficients. Average baseline KCCQ OS calculated scores for Group A
(intervention group) were 45.25, and 31.18 for Group B (control group) (see Table 3).
Mean change after three months was +3.7 points for Group A, with only two follow-up
questionnaires completed, and +11.78 points for Group B, with all five participants
completing a second questionnaire. Differences of KCCQ OS at baseline and after three
months were compared on Group B, using the Wilcoxon Signed Rank Test,
which determined that there was no significant statistical difference between baseline
KCCQ scores and after three months (alpha = 0.05, significance level = 0.080) (see Table
4). However, validity testing of the KCCQ has determined that a 5-point change is
considered clinically significant, in which case Group B shows a significant clinical
difference for all five participants in the control group.
A third group, which was labeled Group C (n=9), were clinically eligible to
participate, but declined to do so (n=3) or were lost to follow-up (n=6). The baseline OS
scores for this group was 29.06 points. Those whose KCCQ scores did not qualify them
for inclusion was labeled Group D (n=7), with an average OS score calculated at 72.69
points.
Baseline characteristics of age, gender, and race were collected after completion
of project implementation and evaluated for reference purposes only and not included in
statistical analysis. It should be noted, however, that compared to the population of the
HFC and the larger community, a disproportionate percentage (90%) of Caucasian males
were inadvertently included in the cohort. The other 10% was Caucasian female. Goals of
care, advance directives, and personal preferences about direction of care were noted
anecdotally.
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Results and Discussion
Findings from this project reflect several aspects found in other studies conducted
on this topic. Results of the KCCQ scores show that patients with HF carry a high
symptom burden that impacts daily life. One of the appealing aspects of the KCCQ is that
it measures five domains of HF-specific quality of life assessments, including the
frequency, severity, and impact of symptoms; physical function; quality of life; social
limitations; self-efficacy; and the stability of symptoms over previous 2-week recall
period (Spertus, 2016). It is validated and widely used to evaluate disease-specific status
in this population.
Within this project results varied from between about which symptoms, and to
what degree, were most distressing, and the impact those symptoms had on QoL. Of the
five original Group A members, only two completed 3-month follow-up questionnaires.
The three who did not complete a second questionnaire still contributed valuable
information to the project. Of these, two were hospitalized for acute decompensation of
HF and were discharged home on hospice. The other one improved clinically enough to
not require follow-up in the HFC within the 3-month period. Although this project did
not result in statistically significant findings, there were clinically significant
improvements noted in both groups. Interpretation of this may include the patient
health status on the day that the questionnaire was administered, because of the potential
for rapid changes in health status for HF patients. Other factors include the optimization
of medications, improved life choices, and education that is a routine part of usual care
leading to improved personal disease management.
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Prognostication of HF is difficult, and the disease trajectory is unpredictable.
Patients who have been recently diagnosed, or those who have been stable for a long
period of time, may not be mentally prepared to have difficult conversations about goals
of care and treatment options. For them, a grieving process may be necessary before
considering the “what ifs”. For this reason, a longitudinal process is an important part of
both HF management and PC considerations. Establishing trust and rapport between
patient and clinician promotes a shared decision-making process. Clinicians are
responsible for informing patients of valid and appropriate treatment options, and patients
are responsible for articulating their wishes. This is difficult for many, so incorporating
family and caregivers into discussions and care planning is valuable.
For this study there was an unintentional racial and gender disparity that did not
reflect the population of the HFC or that of the larger community. In the study groups,
90% (n=9) were Caucasian men, and the other 10% (n=1) Caucasian female. Participants
were aged 61-81 years. These data were gathered after the completion of the project and
was an unintended consequence of that particular admission group during the
enrollment period. Cultural considerations must also be taken into consideration
about how people view and value life and death.
Health literacy and bi-directional communication is a relatively new concept in
health care. Patients with HF tend to be older and still commonly rely on clinicians to
make health decisions for them. They are often ill prepared to participate in discussions
concerning health care decisions. Without proper understanding of the scope of options
and the effects of different treatments, patients are at risk for poorly made decisions.
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There are many variables that affect the course of HF over time. Some of these
variables are controllable, while others are not. Health care providers should be educated
about prognostic indicators that affect disease trajectory and be willing to initiate
conversations with patients whose condition begins to decline. Recognizing clinical
milestones such as increasing frequency of hospitalizations, worsening functional status,
decreased tolerance to HF medications, and worsening end-organ function as
opportunities to re-evaluate patient wishes and goals is an important element to
clarifying the direction of care.
Conclusions
As the U.S. population continues to age, and chronic diseases such as HF become
more prevalent, strategies should be implemented to improve patient outcomes, increase
patient-centered care, promote open communication and shared decision-making, and
optimize resource management. Comprehensive HF treatment should include PC
principles throughout the course of care, regardless of whether treatment is focused on
amelioration of symptoms or prolonging life with advanced therapies. Evidence-based
HF management includes integrating PC into routine treatment, though more clinical
trials are needed to determine best practices.
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DNP Project Product
Professional Journal Selection
Heart & Lung: The Journal of Acute and Critical Care
Scope of Journal
This journal is the official publication of The American Association of Heart
Failure Nurses, and presents original, peer-reviewed articles on techniques, advances,
investigations, and observations related to the care of patients with acute and critical
illness and patients with chronic cardiac or pulmonary disorders. The Journal’s heart
failure articles focus on all aspects of the care of patients with this condition.
Aims of Journal
The aim of the Journal is to publish articles that represent a broad range of science
and clinical practice in a variety of settings as it pertains to the target population. Authors
are encouraged to submit manuscripts that reflect the global, interdisciplinary,
multidisciplinary, and transdisciplinary nature of health care and health sciences.
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Integrating the Palliative Care Principles of Shared Decision-Making and
Advance Care Planning into Heart Failure Management
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Abstract
Background: Heart failure (HF) is a complex syndrome with high mortality rate, frequent
hospitalizations, and significant symptom burden. Palliative care (PC),
historically associated with end-of-life care for cancer patients, offers opportunities to
improve health-related quality of life in conjunction with life-prolonging medical
therapies.
Objectives: To evaluate and address needs of patients with HF.
Methods: Within a hospital-affiliated heart failure clinic, two randomly assigned groups
of recently hospitalized patients were administered The Kansas City Cardiomyopathy
Questionnaire at baseline and after three months. Groups received either usual care or
usual care plus PC intervention. Scores were compared after three months.
Results: Although no statistically significant change was found using the Wilcoxon
Signed-Rank test, clinically significant change was found in both groups.
Conclusions: Emphasizes the need for concurrent guideline-directed HF therapy and
palliative interventions. Long-term, consistent care is essential for patients to achieve
care that is congruent with their needs and wishes.
Keywords: Heart failure, palliative care, shared decision-making, health-related
quality of life, patient-centered care, advance directives
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Integrating the Palliative Care Principles of Shared Decision-Making and Advance
Care Planning into Heart Failure Management
Introduction
Identification of Problem
Heart failure (HF) is a chronic, progressive disease that carries significant
burden to patients, families, and health systems in the U.S. HF is a leading cause of
hospitalization, with frequent readmissions. Morbidity and mortality rates
1

are high, contributing to nearly 10% of all deaths, and has a five year mortality rate of
about 50% . Incorporating palliative care services into standard treatment for advanced
2

HF is widely recommended to improve health-related quality of life (QoL) and to
provide patients and families the opportunity to discuss treatment options and wishes.

3

Another proposed benefit is the opportunity manage common symptoms of dyspnea,
fatigue, pain, depression, edema, and anxiety. Although most HF management guidelines
4

and consensus statements recommend the integration of specialist-directed palliative care
into the management of HF, less than 10% of qualified patients receive these services.

5

Palliative Care (PC) is defined by the World Health Organization (WHO) as an
approach to care that focuses on improving the quality of life of patients facing serious,
complex, or life-threatening illness. In 2015, the WHO expanded the definition and goals
6

of PC to include early application in the disease process in conjunction with treatments
aimed at prolonging life. Redefining the terminology has expanded inclusion criteria to
6

patients with chronic illnesses, including those where prognosis and life expectancy are
difficult to predict, and is not limited to a particular care setting. PC, frequently thought
7

to be interchangeable with hospice, or end of life care, rather focuses on patient and
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familial support throughout the course of serious illnesses, regardless of life-prolonging
or curative treatment. By providing palliative measures throughout the continuum of
4

illness, care becomes patient- and family-centered, thus addressing their physical,
intellectual, emotional, social, and spiritual needs. Facilitating patient autonomy, access
8

to information, and informed choices encourages collaboration and coordination of highquality care. Palliative medicine strives to improve patients’ quality of life using a
8

holistic, multidisciplinary approach to address physical, psychological, and spiritual
needs.

4

Heart Failure (HF) is a complex clinical syndrome resulting from other diseases
or injuries such as myocardial infarction, valvular disease, hypertension, or atrial
fibrillation which damages the myocardium and affects the heart’s ability to pump
effectively. Heart failure is classified as either systolic, characterized by low ejection
9

fraction (EF) and reduced left ventricular contractility; or diastolic, characterized
by impaired relaxation of the heart muscle resulting in abnormal left ventricular filling
capacity, thus maintaining a preserved EF in spite of decreased cardiac output. This
9

failure of the myocardium to pump or to relax adequately is representative of the endstage sequelae of other diseases, typically those involving the cardiac or pulmonary
systems, though other causes should not be excluded. Advances in medical management
9

have improved mortality for patients with systolic heart failure, however these treatments
have not proven beneficial for those with diastolic failure.

9

HF is progressive in nature and has a high mortality rate with associated poor
quality of life, in spite of recent advances in treatment options. For many patients the
10

disease progression is disabling. Common symptoms of HF include dyspnea and angina,
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progressing from occurring primarily with exertion to occurring even at rest. Fatigue is a
common complaint and negatively affects quality of life. Orthopnea and paroxysmal
nocturnal dyspnea interfere with sleep and rest, and persistent edema may limit activity.

9

The disease trajectory is typically marked with periods of relatively stable symptoms
interrupted by acute decompensations. Functional decline may be abrupt or incremental,
with about 50% of HF patients dying abruptly from sudden cardiac death, while the other
half die after gradual debilitation and decline. Prognostication is difficult because the
9

disease trajectory varies widely from patient to patient.

9

Advanced stages of HF carry significant symptom burden and patients commonly
have multiple comorbidities. Although most HF guidelines and consensus statements
recommend PC as a component of routine HF management, PC typically is not
introduced until the patient enters the final stages of life and becomes eligible for
hospice. Unlike hospice, PC services are available to patients at any stage of disease,
9

even those pursuing curative or life-prolonging treatment. Care is focused on maintaining
quality of life through shared decision-making, symptom management, establishing
personal goals, advance planning, and spiritual and psychosocial support.
Significance to Health Care
The prevalence and impact of HF places a significant burden on the health care
system and is expected to increase further as the population of the U.S. ages. In the U.S.,
6.6 million adults are diagnosed with HF, and the American Heart Association
(AHA) expects this number to rise to almost 10 million by 2030, with 670,000 new cases
diagnosed each year. HF accounts for more than 1 million hospitalizations and 3.6
11
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million medical clinic and emergency room visits each year. Direct medical costs for
11

treatment are expected to increase from $21 billion in 2012 to $53 billion by 2030.

11

Within the cardiology literature, there is a paucity of primary research and clinical
trials pertaining to palliative care measures in HF treatment programs. However,
secondary data sources provide validation that this topic is being reviewed as pertinent to
practice. In the past year several changes have been made to AHA and American College
of Cardiology (ACC) Guidelines to implement palliative principles into routine HF
care. Palliative medicine journals provide more qualitative studies and offer methods to
bridge the gap between traditional oncology-focused palliative interventions and those
that are appropriate for HF patients.
In spite of the increased call to implement measures to include palliative care in
the treatment of HF, few patients receive these interventions until they are at the end of
life. There is a discrepancy between expert recommendations and guidelines, and the
resources available to study and implement these measures. Without a solid base of
evidence, utilization of these recommendations will be limited.
Material and Methods
The Heart Failure Clinic (HFC) is a hospital-affiliated, nurse practitionerled outpatient clinic. The role of the clinic is to provide ongoing guidelinedirected management and support for patients with acute and chronic HF, with the goals
of improving patient outcomes, decreasing frequency of HF-related hospitalizations, and
optimizing resource utilization. Patients’ scheduled appointments are made as indicated
by health status, medication stability, and ongoing evaluation. Initial clinical
information is collected by registered nurses (RNs), and evaluation and treatment are
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performed by nurse practitioners (NP). Physician support is available. The HFC is
managed by an NP who is actively involved in program development, functions as a
liaison between the clinic and hospital administration, and represents the clinic within the
community and hospital setting.
Treatment is focused on managing the disease process with the intent to slow
progression and decrease frequency of acute decompensations. An average of 45-60
patients are seen daily by a staff of NPs, RNs, patient care technicians, and physicians.
Medical treatment is guided by the AHA’s Get with the Guidelines (GWTG) for
treatment of HF using current best-practice strategies. The patient population
12

includes adults aged 19 years and older, although approximately 75% of patients are 65
years and older. The gender distribution is generally 60% males, 40% females, and race
distribution is 65% African American, 35% Caucasian.
Sample and Participant Selection
Eligibility criteria for inclusion in this project was defined as: adults 19-years and
older, with New York Heart Association (NYHA) Class III-IV symptoms (see Table
1) and/or have AHA Stage C-D disease (see Table 2) who score 60 or below on the
Kansas City Cardiomyopathy Questionnaire (KCCQ) (see Appendix A) Overall Summary
(OS) score. Gender, age, and race information were collected for reference only after
completion of the project. Clinical judgment, prognostic indicators, and clinical
milestones (disease progression refractory to optimized therapy, increased symptom
burden, and recurrent hospitalizations) were used to guide appropriateness for
participation.
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Patients who were enrolled during the 30-day recruitment period were
administered the KCCQ by a nurse at their first appointment. There were 26
KCCQs administered in the one month of recruitment. Of those, 19 patients met the
inclusion criteria using a convenience selection strategy and were approached to
participate in the project. Of these 19, three patients declined to participate, and six were
lost to follow-up. Seven patients did not meet inclusion criteria, thus were excluded.
Those patients whose baseline KCCQ OS score was 60 or below were considered
eligible for inclusion and were asked to participate in this project using a prepared script.
The patients who agreed to participate (n=10) were randomly allocated in a 1:1
fashion into two groups, Group A (n=5) or Group B (n=5). Group A received usual care
plus the palliative intervention (UC+PC) in the HFC, while Group B received UC alone.
The UC component was managed by the HFC staff utilizing guideline directed therapies,
medication titrations, and ongoing monitoring of end-organ function. The PC intervention
was conducted by an NP dually trained in HF and PC.
Project Design
After obtaining informed consent, face-to-face meetings were scheduled with each
patient in Group A. Interviews were semi-structured, consisting of open-ended questions
to determine patient readiness to participate in shared decision-making, address advanced
directives, and help patients to understand disease trajectory and prognosis. Patientreported quality of life measures were discussed using baseline KCCQ scores to identify
symptoms with the greatest impact on daily life, leading to individualized goal-setting
and attainment strategies.
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The KCCQ is a validated and reliable self-administered 23-item tool that
quantifies six HF-specific domains and two summary scores, the Clinical Summary (CS)
score and the OS score. The selected score to determine inclusion was an OS score of
13

60. Scores were calculated and transformed into values that range from 0-100, with
higher scores representing better health status and patient-perceived HRQoL. Licensure
14

to use the KCCQ was purchased through Outcomes Instruments, LLC.
Detailed discussions to inform patients about treatment options included disease
trajectory, prognostic indicators, and the benefits and burdens of available advanced
therapy options. Medications, titrations, and rationale for each were discussed. If device
implantation was being considered, such as automated implantable cardioverter
defibrillator (AICD), or implanted volume monitoring devices, the risks and
benefits were explained. Advanced therapy options for end-stage heart failure include
inotrope infusions, ultrafiltration, implantation of left ventricular assist device (LVAD),
and heart transplant; the implications were discussed if appropriate. Careful word choice
was imperative to appropriately inform patients without causing undue fear.
Patients were offered the state Advance Directives (AD) documentation to
review. They were also given the opportunity to discuss AD in detail if desired, however
none accepted during the project.
Participants were queried about symptoms, which were then discussed
with pharmacological and nonpharmacological treatment options. Spiritual and
psychosocial concerns were addressed based on patient preference.
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Theory/Calculation
A total of 26 KCCQs were completed during a one-month period. Of these, 19
met criteria to participate, seven scored above the cut-off of 60 calculated points. The
KCCQ OS score at baseline and 3-months were selected as the primary indicator of
change in HRQoL between the two groups, UC or UC+PC intervention. Primary
endpoints were measured by changes in baseline and 3-month OS scores on KCCQ. A 5point change in the KCCQ OS score is the smallest increment that is considered clinically
significant for individual patients.

15

Statistical analysis was performed using SPSS 25.0 software on the primary
endpoint of measurement of QoL using the KCCQ OS score. The sample size was 10
(five per group), though only two post-intervention scores were obtained from Group A,
thus not meeting criteria for an adequate sample size of at least three to measure
correlation coefficients. Average baseline KCCQ OS calculated scores for Group A
(intervention group) were 45.25, and 31.18 for Group B (control group) (see Table 3).
Mean change after three months was +3.7 points for Group A, with only two follow-up
questionnaires completed, and +11.78 points for Group B, with all five participants
completing a second questionnaire. Differences of KCCQ OS at baseline and after three
months were compared on Group B, using the Wilcoxon Signed Rank Test,
which determined that the null hypothesis be retained, there was no significant
statistical difference between baseline KCCQ scores and after three months (alpha = 0.05,
significance level = 0.080) (see Table 4). However, validity testing of the KCCQ has
determined that a 5-point change is considered clinically significant, in which case Group
B shows a significant clinical difference for all five participants in the control group.
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A third group, which was labeled Group C (n=9), were clinically eligible to
participate, but declined to do so (n=3) or were lost to follow-up (n=6). The baseline OS
scores for this group was 29.06 points. Those whose KCCQ scores did not qualify them
for inclusion was labeled Group D (n=7), with an average OS score calculated at 72.69
points.
Baseline characteristics of age, gender, and race were collected after completion
of project implementation and evaluated for reference purposes only and not included in
statistical analysis. It should be noted, however, that compared to the population of the
HFC and the larger community, a disproportionate percentage (90%,) of Caucasian males
were inadvertently included in the cohort. The other 10% was Caucasian female. Goals of
care, advance directives, and personal preferences about direction of care were noted
anecdotally.
Ethical Considerations
Approval from the IRB committees of both the university and the hospital were
obtained prior to initiating this scholarly project. Informed consent was obtained from all
participants in Group A. Interviews were conducted in an office separate from the open
clinic, but in the same suite. No preferential treatment or compensation was given to
those participating in the project. Written and electronic records containing any Protected
Health Information (PHI) were maintained in a locked file.
Results and Discussion
Findings from this project reflect several aspects found in other studies conducted
on this topic. Results of the KCCQ scores show that patients with HF carry a high
symptom burden that impacts daily life. One of the appealing aspects of the KCCQ is that
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it measures five domains of HF-specific quality of life assessments, including the
frequency, severity, and impact of symptoms on physical function, quality of life, social
limitations, self-efficacy, and the stability of symptoms over previous 2-week recall
period. It is validated and widely used to evaluate disease-specific status in this
13

population.
The results from this project showed a variation in which symptoms, and to what
degree, were most distressing, and the impact those symptoms had on QoL. Of the five
original Group A members, only two completed 3-month follow-up questionnaires. The
three who did not complete a second questionnaire still contributed valuable information
to the project. Of these, two were hospitalized for acute decompensation of HF and were
discharged home on hospice. The other one improved clinically enough to not require
follow-up in the Clinic within the 3-month period. Although this project did not result
in statistically significant findings, there were clinically significant improvements noted
in both groups. Interpretation of this may include the patient health status on the day that
the questionnaire was administered, because of the potential for rapid changes in health
status for HF patients. Other factors include the optimization of medications, improved
life choices, and education that is a routine part of usual care leading to improved
personal disease management.
Prognostication of HF is difficult, and the disease trajectory is unpredictable.
Patients who have been recently diagnosed, or those who have been stable for a long
period of time, may not be mentally prepared to have difficult conversations about goals
of care and treatment options. For them, a grieving process may be necessary before
considering the “what ifs”. For this reason, a longitudinal relationship is an important part
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of both HF management and PC considerations. Establishing trust and rapport between
patient and clinician promotes a shared decision-making process. Clinicians are
responsible for informing patients of valid and appropriate treatment options, and patients
are responsible for articulating their wishes. This is difficult for many, so incorporating
family and caregivers into discussions and care planning is valuable.
For this project there was an unintentional racial and gender disparity that did not
reflect the population of the HFC or that of the larger community. In the project groups,
90% (n=9) were Caucasian men, and the other 10% (n=1) Caucasian female. Participants
were aged 61-81 years. These data were gathered after the completion of the project and
was an unintended consequence of that particular admission group during the
enrollment period. Cultural considerations must also be taken into consideration
about how people view and value life and death.
Health literacy and bi-directional communication is a relatively new concept in
health care. Patients with HF tend to be older and still commonly rely on clinicians to
make health decisions for them. They are often ill prepared to participate in discussions
concerning health care choices. Without proper understanding of the scope of options and
the effects of different treatments, patients are at risk for poorly made decisions.
There are many variables that affect the course of HF over time. Some of these
variables are controllable, while others are not. Health care providers should be educated
about prognostic indicators that affect disease trajectory and be willing to initiate
conversations with patients whose condition begins to decline. Recognizing clinical
milestones such as increasing frequency of hospitalizations, worsening functional status,
decreased tolerance to HF medications, and worsening end-organ function as
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opportunities to re-evaluate patient wishes and goals is an important element to
clarifying direction of care.
Conclusion
As the U.S. population continues to age, and chronic diseases such as HF
becomes more prevalent, strategies should be implemented to improve patient outcomes,
increase patient-centered care, promote open communication and shared decisionmaking, and optimize resource management. Comprehensive HF treatment should
include PC principles throughout the course of care, regardless of whether treatment is
focused on amelioration of symptoms or prolonging life with advanced therapies.
Evidence-based HF management includes integrating PC into routine treatment, though
more clinical trials are needed to determine best practices.
Funding
This project did not receive any specific grant from funding agencies in the
public, commercial, or not-for-profit sectors.
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Table 1. New York Heart Association heart failure symptoms classification

Table 2. American Heart Association heart failure stages
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Table 3. KCCQ group scores and averages
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Table 4. SPSS Calculation Tables

56

Figures
Figure 1. QCM Model
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Appendix B
University of Alabama in Huntsville IRB Approval

☒ Expedited (see pg. 2)
☐ Exempted (see pg. 3)
☐ Full Review
☐ Extension of Approval

May 31 , 2018
st

Elizabeth Bolint
College of Nursing
University of Alabama in Huntsville
Elizabeth Bolint,
The UAH Institutional Review Board of Human Subjects Committee has
reviewed your proposal, Integrating the Palliative Care Measures of Shared Decision
Making and Advance Directives into Routine Heart Failure Management, and found it
meets the necessary criteria for approval. Your proposal seems to be in compliance with
this institutions Federal Wide Assurance (FWA) 00019998 and the DHHS Regulations
for the Protection of Human Subjects (45 CFR 46).
Please note that this approval is good for one year from the date on this letter. If
data collection continues past this period, you are responsible for processing a renewal
application a minimum of 60 days prior to the expiration date.
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No changes are to be made to the approved protocol without prior review and
approval from the UAH IRB. All changes (e.g. a change in procedure, number of
subjects, personnel, study locations, new recruitment materials, study instruments, etc.)
must be prospectively reviewed and approved by the IRB before they are implemented.
You should report any unanticipated problems involving risks to the participants or others
to the IRB Chair.
If you have any questions regarding the IRB’s decision, please contact me.
Sincerely,

Bruce Stallsmith
IRB Chair
Professor, Biological Sciences
Expedited:

☐ Clinical studies of drugs and medical devices only when condition (a) or (b) is met. (a) Research on drugs for which
an investigational new drug application (21 CFR Part 312) is not required. (Note: Research on marketed drugs that
significantly increases the risks or decreases the acceptability of the risks associated with the use of the product is not
eligible for expedited review. (b) Research on medical devices for which (i) an investigational device exemption
application (21 CFR Part 812) is not required; or (ii) the medical device is cleared/approved for marketing and the medical
device is being used in accordance with its cleared/approved labeling.

☐ Collection of blood samples by finger stick, heel stick, ear stick, or venipuncture as follows: (a) from healthy,
nonpregnant adults who weigh at least 110 pounds. For these subjects, the amounts drawn may not exceed 550 ml in an
8 week period and collection may not occur more frequently than 2 times per week; or (b) from other adults and children,
considering the age, weight, and health of the subjects, the collection procedure, the amount of blood to be collected, and
the frequency with which it will be collected. For these subjects, the amount drawn may not exceed the lesser of 50 ml
or 3 ml per kg in an 8 week period and collection may not occur more frequently than 2 times per week.

☐ Prospective collection of biological specimens for research purposes by noninvasive means. Examples: (a) hair and
nail clippings in a nondisfiguring manner; (b) deciduous teeth at time of exfoliation or if routine patient care indicates a
need for extraction; (c) permanent teeth if routine patient care indicates a need for extraction; (d) excreta and external
secretions (including sweat); (e) uncannulated saliva collected either in an unstimulated fashion or stimulated by chewing
gumbase or wax or by applying a dilute citric solution to the tongue; (f) placenta removed at delivery; (g) amniotic fluid
obtained at the time of rupture of the membrane prior to or during labor; (h) supra- and subgingival dental plaque and
calculus, provided the collection procedure is not more invasive than routine prophylactic scaling of the teeth and the
process is accomplished in accordance with accepted prophylactic techniques; (i) mucosal and skin cells collected by
buccal scraping or swab, skin swab, or mouth washings; (j) sputum collected after saline mist nebulization.
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☐ Collection of data through noninvasive procedures (not involving general anesthesia or sedation) routinely employed
in clinical practice, excluding procedures involving x-rays or microwaves. Where medical devices are employed, they
must be cleared/approved for marketing. (Studies intended to evaluate the safety and effectiveness of the medical device
are not generally eligible for expedited review, including studies of cleared medical devices for new indications).

☐ Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected
solely for nonresearch purposes (such as medical treatment or diagnosis).
☐ Collection of data from voice, video, digital, or image recordings made for research purposes.
☒ Research on individual or group characteristics or behavior (including, but not limited to, research on perception,
cognition, motivation, identity, language, communication, cultural beliefs or practices, and social behavior) or research
employing survey, interview, oral history, focus group, program evaluation, human factors evaluation, or quality
assurance methodologies.

Exempt
☐ Research conducted in established or commonly accepted educational settings, involving normal educational
practices, such as (a) research on regular and special education instructional strategies, or (b) research on the
effectiveness of or the comparison among instructional techniques, curricula, or classroom management methods. The
research is not FDA regulated and does not involve prisoners as participants.

☐

Research involving the use of educational tests (cognitive, diagnostic, aptitude, achievement), survey procedures,

interviews, or observation of public behavior 1 in which information is obtained in a manner that human subjects cannot
be identified directly or through identifiers linked to the subjects and any disclosure of the human subject’s responses
outside the research would NOT place the subjects at risk of criminal or civil liability or be damaging to the subject’s
financial standing, employability, or reputation. The research is not FDA regulated and does not involve prisoners as
participants.

☐

Research involving the use of educational tests (cognitive, diagnostic, aptitude, achievement) survey procedures,

interview procedures, or observation of public behavior if (a) the human subjects are elected or appointed public officials
or candidates for public office, or (b) Federal statute(s) require(s) without exception that the confidentiality of the
personally identifiable information will be maintained throughout the research and thereafter. The research is not FDA
regulated and does not involve prisoners as participants.

☐ Research involving the collection or study of existing data, documents, records, pathological specimens, or diagnostic
specimens, if these sources are publicly available or if the information is recorded by the investigator in such a manner
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that subjects cannot be identified, directly or through identifiers linked to the subjects. The research is not FDA regulated
and does not involve prisoners as participants.

☐ Research and demonstration projects which are conducted by or subject to the approval of department or agency
heads, and which are designed to study, evaluate, or otherwise examine: (i) public benefit or service programs; (ii)
procedures for obtaining benefits or services under those programs;(iii) possible changes in or alternatives to those
programs or procedures; or (iv) possible changes in methods or levels of payment for benefits or services under those
programs. The protocol will be conducted pursuant to specific federal statutory authority; has no statutory requirement
for IRB review; does not involve significant physical invasions or intrusions upon the privacy interests of the
participant; has authorization or concurrent by the funding agency and does not involve prisoners as participants.

☐ Taste and food quality evaluation and consumer acceptance studies, (i) if wholesome foods without additives are
consumed or (ii) if a food is consumed that contains a food ingredient at or below the level and for a use found to be
safe, or agricultural chemical or environmental contaminant at or below the level found to be safe, by the Food and
Drug Administration or approved by the Environmental Protection Agency or the Food Safety and Inspection Service
of the U.S. Department of Agriculture. The research does not involve prisoners as participants.

1

Surveys, interviews, or observation of public behavior involving children cannot be exempt.
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APPENDIX C
Kansas City Cardiomyopathy Questionnaire
The following questions refer to your heart failure and how it may affect your life. Please read and complete the
following questions. There are no right or wrong answers. Please mark the answer that best applies to you.
Heart failure affects different people in different ways. Some feel shortness of breath while others feel fatigue.
Please indicate how much you are limited by heart failure (shortness of breath or fatigue) in your ability to do
the following activities over the past 2 weeks.
Activity

Extremely
Limited

Quite a
bit
Limited

Moderately
Limited

Slightly
Limited

Not at all
Limited

Limited for other
reasons or did
not do the
activity

Dressing yourself

Showering/Bathing

Walking 1 block on level
ground

Doing yardwork,
housework or carrying
groceries

Climbing a flight of stairs
without stopping

Hurrying or jogging (as if
to catch a bus)

2. Compared with 2 weeks ago, have your symptoms of heart failure (shortness of breath, fatigue, or ankle
swelling) changed?
My symptoms of heart failure have become...
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Much

Slightly

Not

Slightly

Much

I’ve had no symptoms over the last 2

worse

worse

changed

better

better

weeks

3. Over the past 2 weeks, how many times did you have swelling in your feet, ankles or legs when you woke up
in the morning?
Every

3 or more times a week, but not

1‐2 times a

Less than once a

Never over the past 2

morning

every day

week

week

weeks

4. Over the past 2 weeks, how much has swelling in your feet, ankles or legs bothered you?
It has been...
Extremely
bothersome

Quite a bit
bothersome

Moderately
bothersome

Slightly
bothersome

Not at all
bothersome

I’ve had no
swelling

5. Over the past 2 weeks, on average, how many times has fatigue limited your ability to do what you want?
All of the
time

Several times
per day

At least
once a day

3 or more times per
week but not every day

1‐2 times
per week

Less than
once a week

Never over the
past 2 weeks

6. Over the past 2 weeks, how much has your fatigue bothered you?
It has been...
Extremely
bothersome

Quite a bit
bothersome

Moderately
bothersome

Slightly
bothersome

Not at all
bothersome

I’ve had no
fatigue

7. Over the past 2 weeks, on average, how many times has shortness of breath limited your ability to do what
you wanted?
All of the
time

Several times
per day

At least
once a day

3 or more times per
week but not every day

1‐2 times
per week

Less than
once a week

Never over the
past 2 weeks

8. Over the past 2 weeks, how much has your shortness of breath bothered you?
It has been ...
Extremely
bothersome

Quite a bit
bothersome

Moderately
bothersome

Slightly
bothersome

Not at all
bothersome

I’ve had no
shortness of breath

9. Over the past 2 weeks, on average, how many times have you been forced to sleep sitting up in a chair or with
at least 3 pillows to prop you up because of shortness of breath?
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Every

3 or more times a week, but not every

1‐2 times a

Less than once a

Never over the past 2

night

day

week

week

weeks

10. Heart failure symptoms can worsen for a number of reasons. How sure are you that you know what to do,
or whom to call, if your heart failure gets worse?
Not at all sure

Not very sure

Somewhat sure

Mostly sure

Completely sure

11. How well do you understand what things you are able to do to keep your heart failure symptoms from
getting worse? (for example, weighing yourself, eating a low salt diet etc.)
Do not understand at

Do not understand very

Somewhat

Mostly

Completely

all

well

understand

understand

understand

12. Over the past 2 weeks, how much has your heart failure limited your enjoyment of life?
It has extremely
limited my enjoyment
of life

It has limited my
enjoyment of
life Quite a bit

It has moderately
limited my enjoyment of
life

It has slightly
limited my
enjoyment of life

It has not
limited my
enjoyment of life at
all

13. If you had to spend the rest of your life with your heart failure the way it is right now, how would you feel
about this?
Not at all satisfied

Mostly dissatisfied

Somewhat satisfied

Mostly satisfied

Completely satisfied

14. Over the past 2 weeks, how often have you felt discouraged or down in the dumps because of your heart
failure?
I felt that way all of
the time

I felt that way most of
the time

I occasionally felt that
way

I rarely felt that
way

I never felt that
way

15. How much does your heart failure affect your lifestyle? Please indicate how your heart failure may have
limited your participation in the following activities over the past 2 weeks.
Activity

Severely
limited

Limited Quite
a bit

Moderately
limited
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Slightly
limited

Did not
limit at
all

Does not apply or
did not do for other
reasons

Hobbies, recreational
activities

Working or doing
household chores

Visiting family or
friends out of your
home

Intimate relationships
with loved ones
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Appendix D
Participant Recruitment Script
Mr./Mrs. ___________, my name is Betsy Bolint. I am a nurse practitioner in the
Heart Failure Clinic. We are trying to improve our care for our patients and want to
ensure that you have a voice in your care. We feel that shared decision-making of
including you and your family/caregiver in planning your care of heart failure and
including your choices in those plans. We want you to understand what all of your
options are, as well as the risks and benefits of each, so that you can help us know you
consider to be important.
I would like to discuss with you about what heart failure is and why you feel how
you do, the medications and procedures that we use to treat heart failure, and what you
may be able to expect over time. Some other things I would like to talk about are more
about you and your wishes, such as personal goals, what you consider to be a “high
quality” life, what brings you joy, and what worries you most about having heart failure.
I want to assure you that there are no “right” or “wrong” answers or choices, so please be
completely honest in your responses.
Some parts of what I would like to talk about may be difficult or unpleasant, so if
you feel uncomfortable at any point please feel free to let me know. I want you to
understand that the treatment you receive in the heart failure clinic will not be affected in
any way by what you tell me in this room or elsewhere. If you choose not to participate,
you will continue to receive the same level of care in the clinic, and there will be no
repercussions whatsoever. If you tell me at any point in time that you do not want to
participate, I will shred all of your personal information.
At this point do you think you are interested in participating in this project?
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Appendix E
Informed Consent Form
You are invited to participate in a research study about improving your health-related
quality of life. This study is designed to help us to better understand what you would like
us to know about guiding your care in regard to heart failure.
The primary investigator is Elizabeth (Betsy) Bolint from the University of Alabama in
Huntsville and the Huntsville Hospital Heart Failure Clinic.
PROCEDURE TO BE FOLLOWED IN THE STUDY: Participation in this study is
completely voluntary. Once written consent is given; you will be asked to participate in at
least 1 individual discussion and complete a questionnaire. Topics that may be discussed
include: your heart failure and some things you may experience as a result of disease
progression, treatment options and choices you may be expected to make about your
treatment, establishing personal goals and wishes, discussion of advance directives, and
prognostication of disease. The questionnaire has 23 questions and asks how heart failure
affects your quality of life in regard to symptoms such as shortness of breath, fatigue, and
activity tolerance. This session is expected to last approximately 30 minutes. A second
30-minute session for further information and care coordination may be requested by the
participant.
DISCOMFORTS AND RISKS FROM PARTICIPATING IN THIS STUDY: There are
no expected health risks associated with your participation. You may become sad or
emotionally upset during this study. If you continue to feel sad or upset, you can ask to
speak with a Social Worker or Chaplain.
EXPECTED BENEFITS: Results from this study can improve your understanding and
involvement in your care and will help the Heart Failure Clinic staff better understand
how you would like to participate in decisions about your care.
INCENTIVES AND COMPENSATION FOR PARTICIPATION: There are no financial
compensations or incentives for participation.
CONFIDENTIALITY OF RESULTS: Participant numbers will be used to record your
data, and these numbers will be made available only to those researchers directly involved
with this study, thereby ensuring strict confidentiality. This consent form will be
destroyed after 3 years. The data from your session will only be released to those
individuals who are directly involved in the research and only using your participant
number.
FREEDOM TO WITHDRAW: You are free to withdraw from the study at any
time. You will not be penalized because of withdrawal in any form. If you choose not to
participate, you will continue to receive the same level of care in the clinic. Investigators
reserve the right to remove any participant from the session without regard to the
participant’s consent.
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CONTACT INFORMATION: If you have any questions, please ask them now. If you
have questions later on, you may contact the Principal Investigator Betsy Bolint in the
Huntsville Hospital Heart Failure Clinic or at exb0002@uah.edu, or the Faculty
Supervisor Dr. Rita Ferguson in UAH at through the University Graduate office at
256-824-6669 or email at: rf0001@uah.edu. If you have questions about your rights as a
research participant, or concerns or complaints about the research, you may contact the
Office of the IRB (IRB) at 256.824.6101 or email the IRB chair Dr. Bruce Stallsmith at
irb.@uah.edu.
If you agree to participate in our research, please sign and date below.
This study was approved by the Institutional Review Board at UAH and will expire in
one year from May 31, 2018.

__________________________________
______
Name (Please Print)

_________________________________
Signature

__________________________________
______
Name of Legally Authorized Representative
(Please Print)
int)
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Date

__________________________________
Signature Date

Appendix F
Interview Topic Guide
Question wording and follow up will be tailored to patient circumstances and phrased
sensitively and appropriately according to context.
Introduction.
To researcher and study.
Nomination of lay and professional caregivers for study.
Issues of future consent and capacity.
Completion of advance statement of preferences.
Completion of consent to interview.
Background and current circumstances.
Current health: what’s been happening?
Main issues related to illness and treatment
Who is providing care and support?
Informal.
Professional.
Current problems/concerns/coping?
Knowledge and understanding of illness and prognosis.
Nature and goals of current treatment.
Future options: proposals, preferences for care and treatment.
Preferences for information: verbal, written, full, partial.
Adequacy and sources of information.
Making decisions and involvement in care.
Preferences regarding involvement/responsibility for decisions about
treatment.
Specific/general options and issues.
Caregivers involvement/influence in decisions (who).
Issues/concerns?
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Thinking about the future.
How does Patient see the future, at this point in time?
Discussed with others (who: family, friends, HCPs)?
Recorded preferences for future care? (As appropriate).
Advance directives
Healthcare power of attorney
Issues/concerns?
Communication.
Review and reflection: how does patient feel about ease and quality of
communication:
with informal caregiver(s)
with Health Professionals
issues/concerns?
Conclusion
Anything else, not discussed?
Confirm personal details (if not known/as appropriate).
Age; former employment; illness history and duration; network of
informal and professional support, family circumstances.
Debriefing.
How does Patient feel after the interview?
Explore concerns, offer contacts for support, bring discussion to a
neutral plane.
Arrangement for follow up.
Thanks!
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Appendix G
KCCQ License Agreement

LICENSE AGREEMENT
THIS LICENSE AGREEMENT is made as of this 06 April 2018, by and between Outcomes
Instruments, LLC, a for‐profit organization in Missouri, whose address is 18 W. 52nd Street, Kansas
City, Missouri, 64112, United States ("Licensor") and University of Alabama‐ Huntsville , a not‐for‐
profit organization in Alabama, whose address is 15100 Wade Point Rd Se, Huntsville, Alabama,
35803, United States ("Licensee").
RECITALS
A. Licensor has rights in certain research methodologies, technical developments, know‐how,
discoveries, works of authorship, questionnaires, registries, study protocols, processes, datasets and
other useful art, whether or not protected by patents, copyrights, trademarks, trade secrets or other
laws protecting intellectual property rights, as more particularly described on Schedule A attached
hereto and incorporated herein by this reference (the “Licensed Properties”).
B. Licensee is engaged in that certain study more particularly described on Schedule B attached
hereto and incorporated herein by this reference (the “Subject Study”).
C. Licensor desires to grant Licensee the right to use the Licensed Properties solely in connection
with the Subject Study, and Licensee desires to use the Licensed Properties in connection therewith,
subject to all of the terms and conditions hereof.
NOW, THEREFORE, in consideration of the premises and the mutual promises and undertakings
contained herein, the parties hereto agree as follows:
1.
2.

. Subject to the terms and conditions hereof, Licensor grants to Licensee a non‐exclusive,
non‐transferable, non‐assignable limited license to use the Licensed Properties solely in
connection with the conduct of the Subject Study.
. As between Licensor and Licensee, Licensee acknowledges that Licensor retains all
ownership rights in and to the Licensed Properties, and any improvements, modifications
and derivatives thereof (whether prepared by Licensor or Licensee or otherwise), and that
except for the rights granted hereunder, Licensee has no right, title or interest in and to the
Licensed Properties. Licensee agrees to reproduce the appropriate copyright legends and/or
trademark symbols on all written or displayed versions of the Licensed Properties and/or
the results attributed to the use thereof. Licensee further acknowledges and understands
that Licensor reserves the right to (i) grant others the license to use the Licensed Properties
and (ii) use the Licensed Properties in its own research and investigations, without the need
to account to Licensee in connection with such activities.
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3.

. In consideration for the license granted hereunder, Licensee shall pay Licensor the license
fees set forth on Schedule C attached hereto and incorporated herein by this reference, at the
times, and in the manner, set forth on such Schedule.
4. . Licensor represents and warrants to Licensee that Licensor has the full power and
authority to execute and deliver this Agreement and to perform its obligations hereunder
without need to obtain the consent of any third party.
5. . Licensor shall have the right to inspect and observe from time to time through such agents
or representatives as Licensor may designate, on Licensee’s site, the activities conducted by
or for Licensee with respect to the Licensed Properties to determine whether Licensee is
using the Licensed Properties in a proper fashion as provided hereunder. To the extent
Licensor is granted access to a patient’s “protected health information” ("PHI"), as such term
is defined in the Health Insurance Portability and Accountability Act of 1996 and the
regulations promulgated thereunder, the parties agree to negotiate and execute a Business
Associates Agreement containing customary covenants regarding the confidentiality and
limited use of such PHI.
6. . Licensee shall keep and maintain comprehensive and accurate records pertaining to its use
of the Licensed Properties, and the status and progress of the Subject Study. Such reports
shall be available for examination by Licensor and its agents or representatives at any time
upon reasonable advance notice.
7. . Licensee agrees that it shall use the Licensed Properties only as permitted hereunder and
further agrees to refrain from modifying, altering or amending the Licensed Properties or
taking any action which could adversely affect the validity, goodwill and reputation thereof.
Upon the termination or expiration of this Agreement, Licensee shall immediately
discontinue all use of the Licensed Properties.
8. . As between Licensor and Licensee, only the Licensor shall have the right to commence or
prosecute any claims or litigation to protect or enforce its rights in and to the Licensed
Properties. Licensee agrees that it will immediately provide notice to Licensor upon learning
of any litigation, whether actual or threatened, against Licensee in connection with
Licensee’s use of the Licensed Properties. Licensee further agrees that it will cooperate fully
with Licensor by providing any information requested by Licensor in any litigation arising in
connection with Licensee’s use of the Licensed Properties.
9. . LICENSEE ACKNOWLEDGES THAT THE LICENSED PROPERTIES ARE LICENSED “AS
IS”, WITH ALL FAULTS. LICENSORHAS MADE NO REPRESENTATION OR WARRANTY THAT
THE LICENSED PROPERTIES ARE SUITABLE FOR LICENSEE’S USE IN CONNECTION WITH T
HESUBJECT STUDY. LICENSEE SHALL RELY ON ITS OWN JUDGMENT IN EVALUATING ITS U
SE OF THE LICENSED PROPERTIES AND ANY OUTCOMESATTRIBUTABLE THERETO, WITHO
UT RELYING ON ANY MATERIAL OR INFORMATION PROVIDED BY LICENSOR. LICENSOR DI
SCLAIMS ANYREPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WI
THOUT LIMITATION ANY REPRESENTATIONS OR WARRANTIES AS
TO THELICENSED PROPERTIES’ MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURP
OSE. IN
NO EVENT SHALL LICENSOR BE LIABLE FOR SPECIAL, CONSEQUENTIAL, EXEMPLARY OR P
UNITIVE DAMAGES. LICENSOR’S LIABILITY HEREUNDER SHALL BE LIMITED TO
LICENSEE’S DIRECT DAMAGESRESULTING FROM LICENSOR’S BREACH OF ANY OF ITS OBLI
GATIONS HEREUNDER WHICH CONTINUES UNREMEDIED FOR THIRTY DAYS AFTER WRIT
TENNOTICE BUT SHALL IN
NO EVENT EXCEED THE AMOUNT OF THE FEES ACTUALLY PAID BY LICENSEE TO LICENSO
R HEREUNDER.
10. . Licensee hereby agrees to hold Licensor harmless of and from and indemnifies it against
any and all losses, liabilities, claims, damages and expenses (including attorneys’ fees and
expenses) which Licensor may incur or be obligated to pay, or for which it may become
liable or be compelled to pay in any action, claim or proceeding for or by reason of any acts,
whether of omission or commission, that may be claimed to be or are actually committed or
suffered by Licensee arising out of Licensee’s use of the Licensed Properties. The provisions
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11.

12.

13.

14.
15.

16.

17.

of this paragraph and Licensee’s obligations hereunder shall survive the expiration or
termination of this Agreement.
. Subject to Section 9 hereof, Licensor hereby agrees to hold Licensee harmless of and from
and indemnifies it against any and all losses, liabilities, claims, damages and expenses
(including attorneys’ fees and expenses) which Licensee may incur or be obligated to pay, or
for which it may become liable or compelled to pay in any action, claim or proceeding for or
by reason of any breach of any representation, warranty or agreement on the part of
Licensor under this Agreement.
. During the term of this Agreement, the parties may have access to trade secrets, proprietary
information, or other sensitive materials belonging to the other which are not generally
known to the public (“Confidential Information”). During the term of this Agreement and for
a period of five (5) years after termination or expiration hereof, the receiving party
("Recipient") agrees to maintain in trust and confidence all Confidential Information of the
other party (the “Disclosing Party”). The Recipient agrees to safeguard the Confidential
Information using the same standard of care it uses to protect its own Confidential
Information. The Recipient will not disclose any Confidential Information to any third party,
or make any use thereof other than as expressly permitted hereby, without the prior written
consent of the Disclosing Party. As used herein, Confidential Information does not include
any information which the Recipient can demonstrate (i) was known to the Recipient or to
the general public at the time of disclosure; (ii) was independently developed by the
Recipient without the use of any of the Confidential Information; or (iii) was disclosed by a
third party without violating any restriction or duty to the Disclosing Party.
. Notwithstanding the general restrictions set forth in Section 12 above, the parties agree
that publication of the results of research activities serves their mutual interests in
improving the quality of health care. Accordingly, Licensee shall be free to publish the results
of its research and development activities carried out with respect to the Licensed
Properties and the Subject Study. Licensee agrees to refer to Licensor and the Licensed
Properties in the bibliography section of the publication.
. Subject to the provisions of Section 15 hereof, this Agreement shall remain in effect from
04/04/2018 to 01/04/2019. Subsequent renewal of this Agreement shall be optionally
available through application through the web site.
. Licensor shall have the right to immediately terminate this Agreement by giving written
notice to Licensee in the event Licensee: (i) fails to perform any of its duties and obligations
set forth herein, and the continuation thereof for thirty (30) days after notice; (ii) files a
petition in bankruptcy or is adjudicated a bankrupt or insolvent, or makes an assignment for
the benefit of creditors; (iii) makes any use of the Licensed Properties not otherwise
expressly permitted herein or (iv) the Subject Study is cancelled, abandoned, withdrawn or
suspended. In such event, Licensee shall immediately cease and terminate its use of any of
the rights granted hereby and shall, upon the request of Licensor, return to Licensor all
records, copies, documents, media and files making use of the Licensed Properties, or furnish
evidence, satisfactory to Licensor, of the destruction thereof.
. The parties further acknowledge that the breach, whether threatened or actual, of any of
the terms hereof by Licensee shall result in immediate, irreparable injury to Licensor and its
goodwill and that accordingly, Licensor shall be entitled to apply for a preliminary and/or
permanent injunction to restrain the threatened or actual violation of the terms hereof by
the Licensee or to compel specific performance of the terms and conditions of this License
Agreement. Nothing set forth herein shall be construed as prohibiting the Licensor from
pursuing any other remedies available for such breach or threatened breach, including the
recovery of damages and costs incurred, together with attorneys’ fees.
.

a. This Agreement together with the exhibits hereto constitutes the entire understanding between
the parties with respect to this Agreement. No change or modification of any of the provisions of this
Agreement shall be effective unless memorialized by an instrument in writing signed by the parties
hereto. All notices required or permitted to be given hereunder shall be given in writing, to the
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parties at their addresses set forth herein, or to such other address with respect to which notice has
been given in accordance herewith. Whenever possible, each provision of this License Agreement
shall be interpreted in such a manner as to be effective and valid under applicable law. If any
covenant or other provision of this Agreement, or portion thereof, under circumstances not now
contemplated by the parties, is invalid, illegal or incapable of being enforced, by reason of any rule of
law, administrative order, judicial decision or public policy, all other conditions and provisions of this
Agreement shall, nevertheless, remain in full force and effect, and no covenant or provision shall be
deemed dependent upon any other covenant or provision unless so expressed herein. The parties
desire and consent that the court or other body making such determination shall, to the extent
necessary to avoid any unenforceability, so reform such covenant, term, condition or other provision
or portion of this Agreement to the minimum extent necessary so as to render the same enforceable
in accordance with the intent herein expressed.
b. This Agreement shall inure to the benefit of Licensor, its successors and assigns. Licensee shall not
have the right to assign this Agreement, or delegate its duties, by operation of law or otherwise,
without first obtaining the written consent of Licensor.
c. This Agreement shall be governed by and construed in accordance with the laws of the State of
Missouri.
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the
day and year first above mentioned.
Outcomes Instruments, LLC *University of Alabama‐ Huntsville *

By: John Spertus
Title: President
“Licensor”

By:
Title:
“Licensee”

SCHEDULE A: LICENSED PROPERTIES
KCCQ – English (US)
This version of the KCCQ has been validated among English‐speaking residents of the US. This zip file
includes two PDF files: the KCCQ itself and scoring instructions.
SCHEDULE B: DESCRIPTION OF STUDY
Project Name
Integrating the Palliative Care Principles of Shared Decision Making and Advanced Directives into
Routine Heart Failure Management
Project Type
Quality Assessment/Improvement
Project Dates
Start: 04/04/2018
End: 01/04/2019
Duration: 275 days
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Enrollment
Sites: 1
Average subjects per site: 150
Total enrollment: 150
Schedule of Use
Administer to subjects thus: every 30 days
Total uses per subject: 9
Total uses: 1,350
Sponsor Name
University of Alabama in Huntsville
Sponsor Type
Other
SCHEDULE C: LICENSE FEES & PAYMENT TERMS
Payment Terms
Payable on Receipt
Total Instrument Fees
$ 115.00
Total License Fee
$ 115.00
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Appendix H
Alabama Advance Directives
ADVANCE DIRECTIVE FOR HEALTH CARE (Living Will and Health Care
Proxy)
This form may be used in the State of Alabama to make your wishes known about what
medical treatment or other care you would or would not want if you become too sick to
speak for yourself. You are not required to have an advance directive. If you do have an
advance directive, be sure that your doctor, family, and friends know you have one and
know where it is located. S
I, ___________________, being of sound mind and at least 19 years old, would like to
make the following wishes known. I direct that my family, my doctors and health care
workers, and all others follow the directions I am writing down. I know that at any time I
can change my mind about these directions by tearing up this form and writing a new
one. I can also do away with these directions by tearing them up and by telling someone
at least 19 years of age of my wishes and asking him or her to write them down.
I understand that these directions will only be used if I am not able to speak for myself.
If I become terminally ill or injured:
Terminally ill or injured is when my doctor and another doctor decide that I have a
condition that cannot be cured and that I will likely die in the near future from this
condition.
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Life sustaining treatment – Life sustaining treatment includes drugs, machines, or
medical procedures that would keep me alive but would not cure me. I know that even if I
choose not to have life sustaining treatment, I will still get medicines and treatments that
ease my pain and keep me comfortable.
Place your initials by either “yes” or “no”: I want to have life sustaining treatment if I am
terminally ill or injured. ____ Yes ____ No
Artificially provided food and hydration (Food and water through a tube or an IV) – I
understand that if I am terminally ill or injured, I may need to be given food and water
through a tube or an IV to keep me alive if I can no longer chew or swallow on my own
or with someone helping me.
Place your initials by either “yes” or “no”: I want to have food and water provided
through a tube or an IV if I am terminally ill or injured. ____ Yes ____ No
If I Become Permanently Unconscious:
Permanent unconsciousness is when my doctor and another doctor agree that within a
reasonable degree of medical certainty I can no longer think, feel anything, knowingly
move, or be aware of being alive. They believe this condition will last indefinitely
without hope for improvement and have watched me long enough to make that decision. I
understand that at least one of these doctors must be qualified to make such a diagnosis.
Life sustaining treatment – Life sustaining treatment includes drugs, machines, or other
medical procedures that would keep me alive but would not cure me. I know that even if I
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choose not to have life sustaining treatment, I will still get medicines and treatments that
ease my pain and keep me comfortable.
Place your initials by either “yes” or “no”: I want to have life-sustaining treatment if I
am permanently unconscious. ____ Yes ____ No
Artificially provided food and hydration (Food and water through a tube or an IV) – I
understand that if I become permanently unconscious, I may need to be given food and
water through a tube or an IV to keep me alive if I can no longer chew or swallow on my
own or with someone helping me.
Place your initials by either “yes” or “no”: I want to have food and water provided
through a tube or an IV if I am permanently unconscious. ____ Yes ____ No
Other Directions: Please list any other things you want done or not done.
In addition to the directions I have listed on this form, I also want the following:
________________________________________________________________________
_____
If you do not have other directions, place your initials here:
____ No, I do not have any other directions. Sect 2. If I need someone to speak for me.
This form can be used in the State of Alabama to name a person you would like to make
medical or other decisions for you if you become too sick to speak for yourself. This
person is called a health care proxy. You do not have to name a health care proxy. The
directions in this form will be followed even if you do not name a health care proxy.
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Place your initials by only one answer: _____ I do not want to name a health care proxy.
(If you check this answer, go to Section 3)
_____ I do want the person listed below to be my health care proxy. I have talked with
this person about my wishes.
First choice for proxy: ________________________________________
Relationship to me: __________________________________________
Address:
____________________________________________________
City: ____________________________ State _______ Zip
___________
Day-time phone number:_________________ Night-time phone number:
__________________
If this person is not able, not willing, or not available to be my health care proxy, this is
my next choice:
Second choice for proxy: _______________________________________
Relationship to me: __________________________________________
Address: ____________________________________________________
City: ____________________________ State _______ Zip ___________
Day-time phone number: __________________Night-time phone number:
________________
Instructions for Proxy
Place your initials by either “yes” or “no”: I want my health care proxy to make
decisions about whether to give me food and water through a tube or an IV. ____ Yes
____ No
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Place your initials by only one of the following:
____ I want my health care proxy to follow only the directions as listed on this form.
_____ I want my health care proxy to follow my directions as listed on this form and to
make any decisions about things I have not covered in the form.
_____ I want my health care proxy to make the final decision, even though it could mean
doing something different from what I have listed on this form. ection 3. The things
listede at I want.
I understand the following:
- If my doctor or hospital does not want to follow the directions I have
listed, they must see that I get to a doctor or hospital who will follow my directions.
- If I am pregnant, or if I become pregnant, the choices I have made on
this form will not be followed until after the birth of the baby.
- If the time comes for me to stop receiving life sustaining treatment or food
and water through a tube or an IV, I direct that my doctor talk about the good and bad
points of doing this, along with my wishes, with my health care proxy, if I have one, and
with the following people:
____________________________________________________________________
____________________________________________________________________
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Your name:
_______________________________________________________
The month, day, and year of your birth:
_________________________________

Your signature:

____________________________________________________
Date signed: _______________________________________________________

I am witnessing this form because I believe this person to be of sound mind. I did not
sign the person’s signature, and I am not the health care proxy. I am not related to the
person by blood, adoption, or marriage and not entitled to any part of his or her estate. I
am at least 19 years of age and am not directly responsible for paying for his or her
medical care.
Name of first witness:
___________________________________
_____________________________________________

Signature:
Date:

_________________________________________________
Name of second witness: _________________________________
Signature:__________________________________________Date:_________________
______tion 6. Signature of Proxy
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I, ____________________________________________, am willing to serve as the
health care proxy. Signature: ________________________________________ Date:
_________________
Signature of Second Choice for Proxy:
I, __________________________, am willing to serve as the health care proxy if the first
choice cannot serve.
Signature: ________________________________________ Date:
_______________________

83

REFERENCES
Adler, E. D., Goldfinger, J. Z., Kalman, J., Park, M. E., & Meier, D. E. (2009). Contemporary
reviews in cardiovascular medicine: Palliative care in the treatment of advanced heart
failure. Circulation, 120, 2597-2606.
http://dx.doi.org/10.1161/CIRCULATIONAHA.109.869123
Allen, L. A., Stevenson, L. W., Grady, K. L., Goldstein, N. E., Matlock, D. D., Arnold, R. M., ...
Spertus, J. A. (2012). Decision making in advanced heart failure, a scientific statement
from the American Heart Association: Endorsed by Heart Failure Society of America and
American Association of Heart Failure Nurses. Circulation, 125, 1928-1952.
http://dx.doi.org/10.1161/CIR.0b013e31824f2173
American College of Cardiology. (2017). 2017 ACC expert consensus decision pathway for
optimization of heart failure treatment: Answers to 10 pivotal issues about heart failure
with reduced ejection fraction. Journal of the American College of Cardiology, 1-30.
http://dx.doi.org/10.1016/j.jacc.2017.11.025
American Heart Association. (2013). Forecasting the impact of heart failure in the United States:
A policy statement from the American Heart Association. Retrieved from
http://circheartfailure.ahajournals.org
American Heart Association. (2017). Get with the guidelines - heart failure. Retrieved from
https://www.heart.org/en/professional/quality-improvement/get-with-the-guidelinesheart-failure
Bekelman, D. B., Nowels, C. T., Retrum, J. H., Allen, L., Shakar, S. S., Hutt, E.., ... Kutner, J. S.
(2011). Giving voice to patients' and family caregivers' needs in chronic heart failure:

84

Implications for palliative care programs. Journal of Palliative Medicine, 14, 1317-1324.
http://dx.doi.org/10.1089/jpm.2011.0179
Brännström, M., & Boman, K. (2014). Effects of a person-centred and integrated chronic heart
failure and palliative home study. PREFER: A randomized controlled study. European
Journal of Heart Failure, 16, 1142-1151. http://dx.doi.org/10.1002/ejhf.151
Centers for Disease Control and Prevention, Division for Heart Disease and Stroke Prevention.
(2016). Heart failure fact sheet. Retrieved from
https://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_heart_failure.htm
Collins, S., & Storrow, A. (2013). Moving toward comprehensive acute heart failure risk
assessment in the emergency department. Journal of the American College of
Cardiology: Heart Failure, 1, 273-280. http://dx.doi.org/10.1016/j.jchf.2013.05.002
Davidson, P., Cockburn, J., Daly, J., & Fisher, R. S. (2004). Patient-centered needs assessment,
19(3), 164-171. Retrieved from https://www.eds.b.ebscohost.com.elib.uah.edu
Duffy, J. R., & Hoskins, L. M. (2003). The quality-caring model: Blending dual paradigms.
Advances in Nursing Science, 26(1), 77-88. Retrieved from https:www.journals.lww.com
Duffy, J. R., & Hoskins, L. M. (2004). Nonpharmacological strategies for improving heart
failure outcomes in the community: A systematic review. Journal of Nursing Care
Quality, 19, 349-360. Retrieved from https://www.eds.b.ebscohost.com.elib.uah.edu
Duffy, J. R., Hoskins, L. M., & Dudney-Brown, S. (2005). Development and testing of a caringbased intervention for older adults with heart failure. Journal of Cardiovascular Nursing,
20(5), 325-333. Retrieved from http://web.a.ebscohost.com.ezproxy3.lhl.uab.edu/ehost/
Evangelista, L. S., Lombardo, D., Malik, S., Ballard-Hernandez, J., Motie, M., & Liao, S.
(2012). Examining the effects of an outpatient palliative care consultation on symptom

85

burden, depression, and quality of life in patients with symptomatic heart failure. Journal
of Cardiac Failure, 18(12), 894-899. http://dx.doi.org/10.1016/j.cardfail.2012.10.019
Evangelista, L., Liao, S., Motie, M., DeMichelis, N., Ballard-Hernandez, J., & Lombardo, D.
(2014). Does the type and frequency of palliative care services received by patients with
advanced heart failure impact symptom burden? Journal of Palliative Medicine, 17, 7579. http://dx.doi.org/10.1089/jpm.2013.0231
Feltner, C., Jones, C. D., Cené, C. W., Zheng, Z., Middleton, J. C., & Jonas, D. E. (2014).
Transitional care interventions to prevent readmissions for persons with heart failure.
Annals of Internal Medicine, 160, 774-784. http://dx.doi.org/10.7326/M14-0083
Gerlich, M. G., Klindtworth, K., Oster, P., Pfisterer, M., Hager, K., & Schneider, N. (2012).
'Who is going to explain it to me so that I understand?' Health care needs and experiences
of older patients with advanced heart failure. European Journal on Aging, 9, 297-303.
http://dx.doi.org/10.1007/s10433-012-1244-6
Ghashghaei, R., Yousefzai, R., & Adler, E. (2016). Palliative care in heart failure. Progress in
Cardiovascular Disease, 58, 455-460. http://dx.doi.org/10.1016/j.pcad.2016.01.002
Goodlin, S. J. (2009). Palliative care in congestive heart failure. Journal of the American College
of Cardiology, 54(5), 386-396. http://dx.doi.org/10.1016/j.jacc.2009.02.078
Heidenreich, P. A., Albert, N. M., Allen, L. A., Bluemke, D. A., Butler, J., Fonarow, G. C., ...
Trogdon, J. G. (2013). Forecasting the impact of heart failure in the United States: A
policy statement from the American Heart Association. Circulation: Heart Failure,
10(11), 1-15. http://dx.doi.org/10.1161/HHF.0b013e318291329a
Kavalieratos, D., Gelfman, L. P., Tycon, L. E., Riegel, B., Bekelman, D. B., Ikejiani, D. Z., ...
Arnold, R. M. (2017). Palliative care in heart failure: Rationale, evidence, and future

86

priorities. Journal of the American College of Cardiology, 70, 1919-1930.
http://dx.doi.org/10.1016/j.jacc.2017.08.036
Kavalieratos, D., Kamal, A. H., Abernethy, A. P., Biddle, A. K., Carey, T. S., Dev, S., ...
Weinberger, M. (2014). Comparing unmet needs between community-based palliative
care patients with heart failure and patients with cancer. Journal of Palliative Medicine,
17, 475-481. http://dx.doi.org/10.1089/jpm.2013.0526
Kydd, A. (2015). Palliative care: From oncology to all nursing arenas - Good practice or scaring
the patients? Maturitas, 81, 446-448. http://dx.doi.org/10.1016/j.maturitas2015.06.003
Mentz, R. J., Tulsky, J. A., Granger, B. B., Anstrom, K. J., Adams, P. A., Dodson, G. C., ...
Rogers, J. G. (2014). The palliative care in heart failure trial: Rationale and design.
American Heart Journal, 168(5), 645-651. http://dx.doi.org/10.1016/j.ahj.2014.07.018
Mulvihill, K. (2015). Palliative care? But I'm not dying! The Journal for Nurse Practitioners, 11,
563-564. http://dx.doi.org/10.1016/j.nurpra.2015.02.012
National Academies Institute of Medicine. (2001). Crossing the quality chasm: A new health
system for the 21st century. Retrieved from
https://www.nationalacademies.org/hmd/~/media/Files/Report%20Files/2001/Crossingthe-Quality-Chasm/Quality%20Chasm202001%20%20report%20brief.pdf
Office of the Legislative Counsel. (2010). Compilation of patient protection and the affordable
care act. Retrieved from https://www.hhs.gov/sites/default/files/ppacacon.pdf
Pokharel, Y., Khariton, Y., Tang, Y., Nassif, M., Chan, P., Arnold, S., ... Spertus, J. (2017).
Association of serial Kansas City Cardiomyopathy Questionnaire assessments with death
and hospitalization in patients with heart failure with preserved and reduced ejection

87

fraction: A secondary analysis of 2 randomized clinical trials. Journal of the American
Medical Association, 2, 1315-1321. http://dx.doi.org/10.1001/jamacardio.2017.3983
Rogers, J. G., Patel, C. B., Mentz, R. J., Granger, B. B., Steinhauser, K. E., Fiuzat, M., ... Tulsky,
J. A. (2017). Palliative care in heart failure: The PAL-HF randomized, controlled trial.
Journal of the American College of Cardiology, 70, 331-341.
http://dx.doi.org/10.1016/j.jacc.2017.05.030
Schwarz, E. R., Baraghoush, A., Morrissey, R. P., Shah, A. B., Shinde, A. M., Phan, A., &
Bharadwaj, P. (2012). Pilot study of palliative care consultation in patients with advanced
heart failure referred for cardiac transplantation. Journal of Palliative Medicine, 15(1),
12-15. http://dx.doi.org/10.1089/jpm.2011.0256
Siouta, N., van Beek, K., Preston, N., Hasselaar, J., Hughes, S., Payne, S., ... Menten, J. (2016).
Towards integration of palliative care in patients with chronic heart failure and chronic
obstructive pulmonary disease: a systematic literature review of European guidelines and
pathways. BMC Palliative Care, 15. http://dx.doi.org/10.1186/s12904-016-0089-4
Smith, M. C., & Parker, M. E. (2015). Nursing theories and nursing practice (4th ed.).
Philadelphia, PA: F.A. Davis Company.
Spertus, J. (2016). Medical device development tool (MDDT) qualification decision summary for
Kansas City Cardiomyopathy Questionnaire (KCCQ) [MDDT Qualification Decision
Summary (MDDT020)]. Retrieved from Food and Drug Administration MDDT:
https://www.fda.gov/downloads/MedicalDevices/ScienceandResearch/MedicalDeviceDe
velopmentToolsMDDT/UCM581761.pdf
Teuteberg, J. J., & Teuteberg, W. G. (2016). Palliative care for patients with heart failure: Expert
analysis. Retrieved from http://www.ACC.org

88

The Joint Commission. (n.d.). Advanced certification in heart failure. Retrieved from
https://www.jointcommission.org
Treece, J., Chemchirian, H., Hamilton, N., Jbara, M., Gangadharan, V., Paul, T., & Baumrucker,
S. J. (2017). A review of prognostic tools in heart failure. American Journal of Hospice
and Palliative Care, 1-9. http://dx.doi.org/10.1177/1049909117709468
World Health Organization. (2018). Palliative care. Retrieved from http://www.who.int/newsroom/fact-sheets/detail/palliative-care
Xie, K., Gelfman, L., Horton, J. R., & Goldstein, N. E. (2017). State of research on palliative
care in heart failure as evidenced by published literature, conference proceedings, and
NIH funding. Journal of Cardiac Failure, 23(2), 197-200.
http://dx.doi.org/10.1016/j.cardfail.2016.10.013
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., ... Wilkoff, B. L.
(2013). 2013 ACCF/AHA Guideline for the management of heart failure: A report of the
American College of Cardiology Foundation/American Heart Association task force on
practice guidelines. Circulation, 128(16), e240-e327.
http://dx.doi.org/10.1161/CIR.0b013e31829e8776

89

